معرفی
Charlotte Vermehren serves as Associate Professor in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen, with an additional appointment as Guest Researcher in the Department of Pharmacy focusing on Social and Clinical Pharmacy. Her research spans clinical pharmacy, pharmacology, and medication safety with particular emphasis on deprescribing practices and pharmacist-led interventions in primary care settings.
Her research interests center on medication review processes, deprescribing protocols for elderly patients, pharmacist-GP collaborations in general practice, and pharmacogenetic applications in Scandinavian healthcare. Dr. Vermehren employs mixed-methods approaches to develop and evaluate complex interventions that improve medication safety, particularly for vulnerable populations including those with dementia and psychiatric conditions.
Analysis of her recent publications (2023-2025) reveals a strong focus on implementation science in clinical pharmacy, with recurring themes of pharmacist integration into primary care teams, development of patient-centered medication review frameworks, and evaluation of deprescribing strategies for high-risk medications like antipsychotics and benzodiazepines. Her work demonstrates methodological diversity including qualitative program theory development, mixed-methods evaluations, and systematic review protocols.
Dr. Vermehren actively contributes to the academic community through conference organization, including the Patientcentreret klinisk farmaci workshop (April 2024) and PCKF workshop (March 2023), where she serves in organizational and committee roles. Her research has garnered attention across social media platforms and academic networks, with multiple publications showing readership on Mendeley and mentions on X (Twitter) and Facebook.
Her collaborative work extends to interdisciplinary medication reviews, development of complex interventions based on pharmacist secondment to general practice, and investigation of predictive biomarkers for personalized therapy. Current projects include the DECADE study (DEprescribing and Care to reduce Antipsychotics in DEmentia), which represents a hybrid effectiveness-implementation approach to improving dementia care.
